Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

2009; Wiley; Volume: 147; Issue: 1 Linguagem: Inglês

10.1111/j.1365-2141.2009.07837.x

ISSN

1365-2141

Autores

Michael Dickinson, David Ritchie, Daniel J. DeAngelo, Andrew Spencer, Oliver G. Ottmann, Thomas Fischer, Kapil N. Bhalla, Angela Liu, Katie Parker, Jeffrey W. Scott, Mark Bishton, H. Miles Prince,

Tópico(s)

Peptidase Inhibition and Analysis

Resumo

Summary There are few treatment options for patients with Hodgkin Lymphoma (HL) who relapse after conventional therapies. Panobinostat is an orally available pan deacetylase inhibitor with evidence of activity in myeloid malignancies and cutaneous T cell lymphoma. Thirteen HL patients were treated with escalating doses of this novel agent in a phase IA/II multicentre study. A computed tomography partial response was achieved in 5/13(38%), and a metabolic response by 18 F‐fluoro‐2‐deoxy‐ d ‐ glucose positron emission tomography scanning in 7/12 (58%) evaluable patients. This report describes the preliminary evidence of anti‐tumour activity seen in the early phase of this study, which recently closed to accrual.

Referência(s)